|
|
Post by _neil on Jun 24, 2015 9:42:09 GMT -5
Can someone please be so kind as to summarize? I can't watch any webcasts for a few more hours. From the posts here, it sounds like they were well focused on execution. That's a good sign.
|
|
|
|
Post by peppy on Jun 24, 2015 9:42:52 GMT -5
Quote: Prescription uptake. Modest so far. I think things are right on the brink of changing that. Media and twitter. Buzz positive. Regarding: Symphony numbers....... stay tuned, I think we are on the brink of some pretty interesting things.
Slide # 13
Attachment Deleted |
|
|
|
Post by cybergym66 on Jun 24, 2015 9:44:32 GMT -5
Quote: Prescription uptake. Modest so far. I think things are right on the brink of changing that. Media and twitter. Buzz positive. Regarding: Symphony numbers....... stay tuned, I think we are on the brink of some pretty interesting things.
Yes, Matt felt we were "on the brink" quite a bit!  |
|
|
|
Post by bradleysbest on Jun 24, 2015 10:07:10 GMT -5
We have been on the "brink" for a long time now....just saying
|
|
|
|
Post by bobw on Jun 24, 2015 10:26:15 GMT -5
Does anyone know what the new chemical entity for the Technosphere platform that Matt mentioned while on slide 18? Matt said that there have been questions about it, probably because the other party has talked about it. I was thinking he was talking about Torrey Pines. "The drug is being developed in partnership with Mannkind Corp., which has created a small device that allows people to inhale medicine. By inhaling, the medicine can relieve pain quicker than through pill form, Houghten said." www.tcpalm.com/business/torrey-pines-could-begin-human-testing-of-new-inI was thinking the same thing, but i haven't heard anything new in a very long time. If his is the case (and I am not speculating that it is), it would mean that there are two different pain medications, one using an approved API and the other a new compound from Torrey Pines. |
|
|
|
Post by peppy on Jun 24, 2015 10:47:14 GMT -5
The second Technosphere application is already in development. It "leapt ahead" and is now "neck and neck" with the first product in development. |
|
|
|
Post by dudley on Jun 24, 2015 11:05:25 GMT -5
My personal sense is this was the most enthusiastic conference YET. Matt was very open in his comments about "paradigm changing", blockbuster product etc. Much more forthcoming about future TI developments. Constant references to how things will soon be changing and they are on the brink. LOVED the comments about his mentor Al, who has remained extremely calm throughout "any time you introduce a paradigm-changing product (which Al HAS, numerous times) a large short interest goes along with it" "Take care of the patients and the stock price takes care of itself" - (remember Minimed was in the $2's at it's darkest hour, only to be sold for $48 when Al finally decided to sell the company).
Small dig at GS when he said his quote there was completely taken out of context "We're not there yet" as regards profitability - which is obvious from the financials. He reiterated that it will rapidly go the other direction with volume production.
HUGE patient preference for Afrezza in surveys over ALL forms of injectables.
It's all going the right direction, just be patient. Remember the market makers are in control of the stock on any given day and will ALWAYS be trying to get the stock as cheaply as they can - don't get psyched out if the stock drops on low volume - that is just falling right into their hands.
|
|
|
|
Post by harryx1 on Jun 24, 2015 11:14:14 GMT -5
"Take care of the patients and the stock price takes care of itself" Listen to this recent podcast with Dexcom's CEO Kevin Sayer who worked for Minimed and Al Mann, he mentions why he went to work for Minimed at the 5 min mark and also talks about the quote above in the podcast. justtalkingpodcast.com/2015/06/16/with-kevin-sayer-ceo-dexcom/ |
|
|
|
Post by savzak on Jun 24, 2015 11:31:24 GMT -5
"Take care of the patients and the stock price takes care of itself" Listen to this recent podcast with Dexcom's CEO Kevin Sayer who worked for Minimed and Al Mann, he mentions why he went to work for Minimed at the 5 min mark and also talks about the quote above in the podcast. justtalkingpodcast.com/2015/06/16/with-kevin-sayer-ceo-dexcom/Regarding Al Mann..."His genius and his persistence and his dreams are mesmerizing." |
|
|
|
Post by Chris-C on Jun 24, 2015 11:50:33 GMT -5
I thought this was Matt's strongest performance yet. There was nothing but positive news, and he avoided saying things that could have been misinterpreted or spun negatively. I thought he did a great job of emphasizing that the quarterly burn rate has been reduced significantly (over 50%) and that they are confident in the pace of development of the other applications as well as satisfied with SNY's approach to marketing Afrezza and being responsive (now) to their target population of prescribing physicians. I think the concierge service SNY implemented to assist physicians with negotiating approvals is a solid indication of this, and I also liked what Matt said about possibly moving up the development of 2 unit cartridges based on user requests. Clearly, Matt is tuned in to what is happening on social media (he specifically mentioned positive feedback on Twitter) and I would not be surprised if he reads this board. I loved his anecdote about Al Mann providing the mentoring and "compass" to stay focused on delivering value for patients and the rest will follow. I was also pleased to see confirmation of a plan to go beyond the Internet and print advertising with some commercials on broadcast media. This was a positive, professional, focused and encouraging presentation. It also communicated that Matt is as "fed up" with the short interest as we are; but he pointed out that it's typical and that they believe they have things well under control. He also inferred many times that he believes we are at a point of inflection with regard to impending growth of weekly scripts. I appreciate the reminder about this conference and encourage everyone to listen. You can here it by signing in here: wsw.com/webcast/jmp27/register.aspx?conf=jmp27&page=mnkd&url=http://wsw.com/webcast/jmp27/mnkd/index.aspxEnjoy! |
|
|
|
Post by babaoriley on Jun 24, 2015 12:12:36 GMT -5
Wow, if this were a Broadway play, the reviews would be off the charts, many happy people at Sardi's!
I think Matt must be taking some communications courses, or perhaps he's been tutored on public speaking (which would have been an excellent idea), he's obviously upped his game - good going, Matt, much appreciated by all MNKD fans!
The feeling of confidence in Afrezza only gets stronger!
|
|
|
|
Post by liane on Jun 24, 2015 12:27:16 GMT -5
Now my interest is piqued - can't listen to it until after work.
|
|
|
|
Post by kball on Jun 24, 2015 12:35:43 GMT -5
I thought this was Matt's strongest performance yet. There was nothing but positive news, and he avoided saying things that could have been misinterpreted or spun negatively. I thought he did a great job of emphasizing that the quarterly burn rate has been reduced significantly (over 50%) and that they are confident in the pace of development of the other applications as well as satisfied with SNY's approach to marketing Afrezza and being responsive (now) to their target population of prescribing physicians. I think the concierge service SNY implemented to assist physicians with negotiating approvals is a solid indication of this, and I also liked what Matt said about possibly moving up the development of 2 unit cartridges based on user requests. Clearly, Matt is tuned in to what is happening on social media (he specifically mentioned positive feedback on Twitter) and I would not be surprised if he reads this board.
I loved his anecdote about Al Mann providing the mentoring and "compass" to stay focused on delivering value for patients and the rest will follow. I was also pleased to see confirmation of a plan to go beyond the Internet and print advertising with some commercials on broadcast media. This was a positive, professional, focused and encouraging presentation. It also communicated that Matt is as "fed up" with the short interest as we are; but he pointed out that it's typical and that they believe they have things well under control. He also inferred many times that he believes we are at a point of inflection with regard to impending growth of weekly scripts. I appreciate the reminder about this conference and encourage everyone to listen. You can here it by signing in here: wsw.com/webcast/jmp27/register.aspx?conf=jmp27&page=mnkd&url=http://wsw.com/webcast/jmp27/mnkd/index.aspxEnjoy! One of my big fears is Matt poaches Harry from here! |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jun 24, 2015 12:43:22 GMT -5
"Take care of the patients and the stock price takes care of itself" Listen to this recent podcast with Dexcom's CEO Kevin Sayer who worked for Minimed and Al Mann, he mentions why he went to work for Minimed at the 5 min mark and also talks about the quote above in the podcast. justtalkingpodcast.com/2015/06/16/with-kevin-sayer-ceo-dexcom/Reminds me of a quote of another great man, George Merck: “We try to remember that medicine is for the patient. We try never to forget that medicine is for the people. It is not for the profits. The profits follow, and if we have remembered that, they have never failed to appear. The better we have remembered it, the larger they have been.“. George Merck, 1950 |
|
|
|
Post by Chris-C on Jun 24, 2015 13:46:09 GMT -5
One other point Matt made that I appreciated was his explanation of why they are not revealing more about the other applications in the pipeline (he did say that the first two —pain and pulmonary applications—were nearly at a point for early clinical studies). As I understood him, the hold up regarding partnership announcements has to do with intellectual property- tying together protections before the "cat is out of the bag", so to speak (to use an idiomatic expression consistent with the affections of this board).
Matt also reiterated the attention being devoted to the pipeline for further commercializing the Technosphere delivery platform, again emphasizing that MNKD has a division of 35 people dedicated to this- and noted that some early stage pharmaceutical companies do not have staffs that large within their total enterprise. I like that he is using examples to give the significance of his remarks more impact, without revealing privileged information and without making claims that would be vulnerable to accusations of pumping.
Chris C
|
|
